Tagged with strategy

Ipsen These are exciting times for Ipsen in Ireland, with plans to expand the company’s already significant API manufacturing footprint to deal with increasing global demand for its products. “Sales from [Somatuline® (lanreotide) and Decapeptyl® (triptorelin)] amounted to over EUR 700 million in 2015, which was over half of Ipsen’s global…

Switzerland The Chief Scientific Officer and President of Glenmark Pharmaceuticals Swiss R&D Center elaborates on Glenmark’s endeavor to venture up the pharmaceutical value chain and discusses the company’s R&D strategy. Furthermore, he highlights the significance of strategic partnerships in today’s pharmaceutical R&D efforts. You have spent 23 years working in large…

Mexico Aimed to ignite a paradigm shift away from the current traditional distributor model, Salumedic’s Managing Director, Gabriel Tagle, shares the novel business concept with zeal and sharp business acumen. He speaks about Saludemic’s core value preposition of being a “commercial hand” to key healthcare players, the crucial importance of proper…

Switzerland The managing director of Stallergenes Greer Switzerland, Claude Fischlewitz, explains how he has gone about revitalizing the company’s presence in Switzerland, while expressing his ambitions to restore and firmly position Stallergenes Greer as the number one provider of total allergy management in the country. Can you please start by providing…

Taiwan Wang Yu Pei, general manager of Nang Kuang Pharmaceutical, Taiwan’s indisputable market leader for injectable products, provides insights into the global ambitions of the company as Nang Kuang is about to bring its first injectable into the US market and is also looking for Europe-based partners to distribute its high-quality…

Switzerland “Get it done! That is what CARBOGEN AMCIS is all about!” – The CEO of the Swiss drug development and commercialization services company elaborates on the company’s strong mindset and declares customer intimacy to be their unique selling point. CARBOGEN AMCIS celebrated its 10th year since joining the Dishman group.…

Mexico Aristides Torres, CEO at Laboratorios Vanquish, explains how the company has evolved during the last five years to serve both the public and private markets and why they have focused on niche market areas with high unmet patient need. Could you please give an update to our international audience about…

Switzerland Backed by the Japanese Zeria Group, fast growing gastrointestinal (GI) specialist Tillotts Pharma is looking to acquire further GI assets after its recent USD 200m M&A deal. The company is looking for assets which generate a turnover of EUR 50 – 150 million in Europe and/or Japan, and also to…

Mexico Xavier Rams, General Director at Ferrer Mexico, explains the importance of aligning corporate strategy to public healthcare goals in order to succeed in the dynamic Mexican environment and showcases the added value that Sincronium® creates for the national healthcare system as a whole. You have been in charge of Ferrer…

Greece The management team of PharOS discuss the company’s move from generics consultancy to co-developer, surviving in the Greek market, and internationalization plans. Founded back in 2002, PharOS has gained a formidable reputation as a pharma development company for bringing best in class generics products to market and prolonging their life…

Taiwan Mike Exton, Managing Director at Novartis Taiwan, describes the affiliate’s plans to increase collaboration with the government in order to provide Taiwanese patients with a greater access to innovative, life-changing products, while highlighting Novartis’ world-class innovation in many critical therapeutic areas, such as heart failure, as well as the skilled…

Greece John Kandylis, GM of Greek logistics market leader Olympias, discusses his company’s unique service offering, negotiating the issues brought about by the financial crisis, and retaining a family-run spirit while expanding internationally. Olympias SA is positioned as a market leader in logistics with deep expertise in the field. Could you…